Cargando…
Levels of whole salivary advanced glycation end products and interleukin-17 and peri-implant clinical and radiographic status in patients with osteoporosis at 6-years’ follow-up
BACKGROUND: There are no studies that have assessed advanced glycation end products (AGEs) and interleukin 17A (IL-17A) levels in whole saliva (WS) of patients with dental implants. The aim was to compare levels of AGEs and IL-17A in WS and peri-implant clinical and radiographic status of patients w...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685916/ https://www.ncbi.nlm.nih.gov/pubmed/36424586 http://dx.doi.org/10.1186/s12903-022-02591-7 |
_version_ | 1784835625301573632 |
---|---|
author | Al-Qahtani, Fawaz Alqhtani, Nasser Divakar, Darshan Devang Alkhtani, Fahad Alqarawi, Firas K. |
author_facet | Al-Qahtani, Fawaz Alqhtani, Nasser Divakar, Darshan Devang Alkhtani, Fahad Alqarawi, Firas K. |
author_sort | Al-Qahtani, Fawaz |
collection | PubMed |
description | BACKGROUND: There are no studies that have assessed advanced glycation end products (AGEs) and interleukin 17A (IL-17A) levels in whole saliva (WS) of patients with dental implants. The aim was to compare levels of AGEs and IL-17A in WS and peri-implant clinical and radiographic status of patients with and without osteoporosis at 6-years’ follow-up. METHODS: Osteoporotic (Group-1) and systemically healthy controls (Group-2) having undergone dental implant therapy at least 5 years ago were included. A questionnaire was used to collect information about age, gender, duration and treatment of osteoporosis, number and duration of implants in function, and frequencies of toothbrushing, flossing and hygiene visits. Modified bleeding and plaque indies (mBI and mPI), peri-implant probing depth (PD) and crestal bone loss (CBL) were recorded. WS was collected and levels of AGEs and IL-17A were determined using enzyme linked immunosorbent assay. Sample-size estimation was done and statistical analyses were doing using the independent t- and Wilcoxon rank-sum tests. Statistical significance was marked for P-values that were below 0.01. RESULTS: In patients with (n = 24) and without (n = 27) osteoporosis, implants were in function for 6.3 ± 0.27 and 6.6 ± 0.5 years, respectively. There was no significant difference in peri-implant mBI, PD, mPI and CBL in both groups. Levels of AGE in patients with (119.6 ± 26.5 μg/ml) and without (91.5 ± 14.6 μg/ml) osteoporosis were comparable. Levels of whole salivary IL-17A in patients without and with osteoporosis were 4.6 ± 0.3 and 5.1 ± 0.8 pg/ml, respectively. Flossing of full mouth interproximal spaces once and twice daily toothbrushing daily was reported by 100% patients with osteoporosis. Among patients with osteoporosis 75% and 25% individuals were receiving professional dental prophylaxis every 4 and 6 months, respectively. CONCLUSION: Within the limitations of the present study osteoporotic patients are not at an increased risk of peri-implant diseases and can demonstrate salivary AGE and IL-17A levels comparable to non-osteoporotic individuals as long as oral hygiene is stringently maintained. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12903-022-02591-7. |
format | Online Article Text |
id | pubmed-9685916 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-96859162022-11-25 Levels of whole salivary advanced glycation end products and interleukin-17 and peri-implant clinical and radiographic status in patients with osteoporosis at 6-years’ follow-up Al-Qahtani, Fawaz Alqhtani, Nasser Divakar, Darshan Devang Alkhtani, Fahad Alqarawi, Firas K. BMC Oral Health Research BACKGROUND: There are no studies that have assessed advanced glycation end products (AGEs) and interleukin 17A (IL-17A) levels in whole saliva (WS) of patients with dental implants. The aim was to compare levels of AGEs and IL-17A in WS and peri-implant clinical and radiographic status of patients with and without osteoporosis at 6-years’ follow-up. METHODS: Osteoporotic (Group-1) and systemically healthy controls (Group-2) having undergone dental implant therapy at least 5 years ago were included. A questionnaire was used to collect information about age, gender, duration and treatment of osteoporosis, number and duration of implants in function, and frequencies of toothbrushing, flossing and hygiene visits. Modified bleeding and plaque indies (mBI and mPI), peri-implant probing depth (PD) and crestal bone loss (CBL) were recorded. WS was collected and levels of AGEs and IL-17A were determined using enzyme linked immunosorbent assay. Sample-size estimation was done and statistical analyses were doing using the independent t- and Wilcoxon rank-sum tests. Statistical significance was marked for P-values that were below 0.01. RESULTS: In patients with (n = 24) and without (n = 27) osteoporosis, implants were in function for 6.3 ± 0.27 and 6.6 ± 0.5 years, respectively. There was no significant difference in peri-implant mBI, PD, mPI and CBL in both groups. Levels of AGE in patients with (119.6 ± 26.5 μg/ml) and without (91.5 ± 14.6 μg/ml) osteoporosis were comparable. Levels of whole salivary IL-17A in patients without and with osteoporosis were 4.6 ± 0.3 and 5.1 ± 0.8 pg/ml, respectively. Flossing of full mouth interproximal spaces once and twice daily toothbrushing daily was reported by 100% patients with osteoporosis. Among patients with osteoporosis 75% and 25% individuals were receiving professional dental prophylaxis every 4 and 6 months, respectively. CONCLUSION: Within the limitations of the present study osteoporotic patients are not at an increased risk of peri-implant diseases and can demonstrate salivary AGE and IL-17A levels comparable to non-osteoporotic individuals as long as oral hygiene is stringently maintained. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12903-022-02591-7. BioMed Central 2022-11-24 /pmc/articles/PMC9685916/ /pubmed/36424586 http://dx.doi.org/10.1186/s12903-022-02591-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Al-Qahtani, Fawaz Alqhtani, Nasser Divakar, Darshan Devang Alkhtani, Fahad Alqarawi, Firas K. Levels of whole salivary advanced glycation end products and interleukin-17 and peri-implant clinical and radiographic status in patients with osteoporosis at 6-years’ follow-up |
title | Levels of whole salivary advanced glycation end products and interleukin-17 and peri-implant clinical and radiographic status in patients with osteoporosis at 6-years’ follow-up |
title_full | Levels of whole salivary advanced glycation end products and interleukin-17 and peri-implant clinical and radiographic status in patients with osteoporosis at 6-years’ follow-up |
title_fullStr | Levels of whole salivary advanced glycation end products and interleukin-17 and peri-implant clinical and radiographic status in patients with osteoporosis at 6-years’ follow-up |
title_full_unstemmed | Levels of whole salivary advanced glycation end products and interleukin-17 and peri-implant clinical and radiographic status in patients with osteoporosis at 6-years’ follow-up |
title_short | Levels of whole salivary advanced glycation end products and interleukin-17 and peri-implant clinical and radiographic status in patients with osteoporosis at 6-years’ follow-up |
title_sort | levels of whole salivary advanced glycation end products and interleukin-17 and peri-implant clinical and radiographic status in patients with osteoporosis at 6-years’ follow-up |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685916/ https://www.ncbi.nlm.nih.gov/pubmed/36424586 http://dx.doi.org/10.1186/s12903-022-02591-7 |
work_keys_str_mv | AT alqahtanifawaz levelsofwholesalivaryadvancedglycationendproductsandinterleukin17andperiimplantclinicalandradiographicstatusinpatientswithosteoporosisat6yearsfollowup AT alqhtaninasser levelsofwholesalivaryadvancedglycationendproductsandinterleukin17andperiimplantclinicalandradiographicstatusinpatientswithosteoporosisat6yearsfollowup AT divakardarshandevang levelsofwholesalivaryadvancedglycationendproductsandinterleukin17andperiimplantclinicalandradiographicstatusinpatientswithosteoporosisat6yearsfollowup AT alkhtanifahad levelsofwholesalivaryadvancedglycationendproductsandinterleukin17andperiimplantclinicalandradiographicstatusinpatientswithosteoporosisat6yearsfollowup AT alqarawifirask levelsofwholesalivaryadvancedglycationendproductsandinterleukin17andperiimplantclinicalandradiographicstatusinpatientswithosteoporosisat6yearsfollowup |